<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Standard intensive induction therapy is tolerated poorly by elderly patients with <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We treated 19 elderly patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, including seven with a prior <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with a combination of low dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>, and GM-CSF </plain></SENT>
<SENT sid="2" pm="."><plain>The percentage of blasts in S-phase was evaluated prior to and 24 hr after starting the GM-CSF infusion </plain></SENT>
<SENT sid="3" pm="."><plain>Cell cycle analysis was performed by flow cytometry using <z:chebi fb="0" ids="51246">propidium</z:chebi> <z:chebi fb="60" ids="24859">iodine</z:chebi> staining with <z:chebi fb="0" ids="37926">fluorescein isothiocyanate</z:chebi>-conjugated monoclonal antibody to the myeloid antigen CD 33 </plain></SENT>
<SENT sid="4" pm="."><plain>Seven out of nineteen (37%) achieved a complete remission (CR) and six (31%) a partial remission (PR) for an overall response rate of 68% (13/19) </plain></SENT>
<SENT sid="5" pm="."><plain>There were three early <z:hpo ids='HP_0011420'>deaths</z:hpo> from infectious complications or organ failure </plain></SENT>
<SENT sid="6" pm="."><plain>One patient died from disseminated <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> after attaining a PR </plain></SENT>
<SENT sid="7" pm="."><plain>The medial overall survival was 9.5 months with a range of 1 to 23+ months </plain></SENT>
<SENT sid="8" pm="."><plain>The projected median survival for the patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is greater than 23 months </plain></SENT>
<SENT sid="9" pm="."><plain>The percentage of CD 33+ cells in S-phase increased from a mean of 11.6+/-2.7 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) pre GM-CSF to 19.0+/-3.7 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) post GM-CSF (P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> demonstrated a greater increment (post-pre) in S-phase activity after GM-CSF administration (P = 0.02) </plain></SENT>
<SENT sid="11" pm="."><plain>There was a correlation between the increase in percent of CD 33+ cells in S-phase and the degree of cytoreduction as determined by the day 14 bone marrow biopsy (r = .78) </plain></SENT>
<SENT sid="12" pm="."><plain>The toxicity of the regimen was limited to the hematopoietic system </plain></SENT>
<SENT sid="13" pm="."><plain>Sixteen out of nineteen patients (84%) and 12/13 (92%) of the responding patients had bone marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> on day 14 </plain></SENT>
<SENT sid="14" pm="."><plain>No patients experienced &gt; grade 2 gastrointestinal toxicity </plain></SENT>
<SENT sid="15" pm="."><plain>There was no neurologic or cardiac toxicity </plain></SENT>
<SENT sid="16" pm="."><plain>These data suggest that the combination of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>, GM-CSF, and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> is an effective remission-induction regimen in elderly patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>